Amount awarded from CPRIT grant.

No definition available.

Name:	scpx_AmountAwardedFromCpritGrant
Namespace Prefix:	scpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount awarded from NIH grant.

+ References

No definition available.

+ Details

Name:	scpx_AmountAwardedFromNihGrant
Namespace Prefix:	scpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents information relating to the total number of customers.

+ References

No definition available.

+ Details

Name:	scpx_NumberOfCustomers
Namespace Prefix:	scpx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of process development contract liability.

+ References

No definition available.

+ Details

Name:	scpx_ProcessDevelopmentContractLiability
Namespace Prefix:	scpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of process development contract liability net changes to contract balance recognized since beginning of period due to amounts collected.

+ References

No definition available.

+ Details

Name:	scpx_ProcessDevelopmentContractLiabilityNetChangeToContractBalance
Namespace Prefix:	scpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of process development contract liability reclassified to revenue as a result of performance obligations satisfied.

+ References

No definition available.

+ Details

Name:	scpx_ProcessDevelopmentContractLiabilityReclassificationToRevenue
Namespace Prefix:	scpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

N/A

+ References

No definition available.

+ Details

Name:	scpx_ProcessDevelopmentRevenueAbstract
Namespace Prefix:	scpx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of process development revenue recognized.

+ References

No definition available.

+ Details

Name:	scpx_ProcessDevelopmentRevenueRecognized
Namespace Prefix:	scpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=scpx_TwoCustomersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=scpx_ThreeCustomersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue (Details)	3 Months Ended		9 Months Ended		12 Months Ended
Revenue (Details)	Sep. 30, 2024 USD ($) customer	Sep. 30, 2023 USD ($) customer	Sep. 30, 2024 USD ($) customer	Sep. 30, 2023 USD ($) customer	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Process Development Revenue
Process development revenue recognized	$ 800,000	$ 600,000	$ 5,000,000.0	$ 2,000,000.0
Process development contract liabilities, beginning of period			(2,389,441)	(1,618,308)	$ (1,618,308)
Reclassification to revenue as the result of performance obligations satisfied			4,891,241	1,962,303
Net change to contract balance recognized since beginning of period due to amounts collected			(4,842,664)	(4,433,141)
Process development contract liabilities, end of period	(2,340,864)	$ (4,089,146)	(2,340,864)	$ (4,089,146)	(2,389,441)
Accounts receivable	$ 203,077		$ 203,077		$ 375,192	$ 81,456
Total recognized revenue \| Customer Concentration Risk \| Two customers
Grant Revenue
Concentration risk, percentage		72.00%		79.00%
Process Development Revenue
Number of customers \| customer		2		2
Total recognized revenue \| Customer Concentration Risk \| Three customers
Grant Revenue
Concentration risk, percentage	59.00%		70.00%
Process Development Revenue
Number of customers \| customer	3		3
Grant and contract revenue
Grant Revenue
Amount awarded from CPRIT grant			$ 200,000
Amount Awarded From NIH Grant	$ 100,000			$ 0